Journal of Clinical Oncology

Vol. 44, Issue 10 Issue 10 2026
14
Articles

Articles in this Issue

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II)

Pablo Hernáiz Driever, Uwe R. Kordes, Ines B. Brecht et al. Apr 01, 2026 pp. 849-860 10.1200/jco-25-01447

PURPOSE Neurofibromatosis type 1 (NF1)–associated plexiform neurofibroma (PN) can substantially affect quality of life. The capsule and granule formulations...

Pediatric-Friendly Formulations: Critical to Maximizing Benefit of Novel Therapeutics Such as Selumetinib for Children With Neurofibromatosis and Other Neoplasms

Brooke Bernhardt, Brenda J. Weigel Apr 01, 2026 pp. 832-834 10.1200/jco-25-02765

Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical <i>EGFR</i> Mutations: A Phase Ib Study

Huaqiang Zhou, Hongyun Zhao, Xue Hou et al. Apr 01, 2026 pp. 893-902 10.1200/jco-25-01929

PURPOSE To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non–small cell lung cancer (NSCLC) harboring actionable ge...

Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging

Floris J. Pos, Karolína Menne Guricová, Jochem R.N. van der Voort van der Zyp et al. Apr 01, 2026 pp. 946-947 10.1200/jco-25-02744

Gene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism

Daniel J. Benedetti, Jonathan M. Marron, Eric Kodish Apr 01, 2026 pp. 835-839 10.1200/jco-25-01844

Incremental Progress in the Cervical Cancer Screening Revolution

L. Stewart Massad Apr 01, 2026 pp. 829-831 10.1200/jco-25-03021

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm

Andrew A. Lane, Luca Mazzarella, David A. Sallman et al. Apr 01, 2026 pp. 861-873 10.1200/jco-25-02083

PURPOSE Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a unique myeloid malignancy with CD123 interleukin-3 receptor-α overexpression and poor prognosis....

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

Lisa K. Hicks, Hans J. Messersmith, Samer Al Hadidi et al. Apr 01, 2026 pp. 914-941 10.1200/jco-25-02587

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...

Quiet Work of Clarity

Henry Bair Apr 01, 2026 pp. 942-944 10.1200/jco-25-02215

An ophthalmology resident discovers how vision care can honor end-of-life goals, helping a cancer patient with failing sight write to his children while considering how and when such letters should be...

Survival Outcomes With or Without Risk-Reducing Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers

Ashu Gandhi, Sacha J. Howell, Elaine F. Harkness et al. Apr 01, 2026 pp. 874-882 10.1200/jco-25-00834

PURPOSE Many women carrying pathogenic variants (pvs) of BRCA1 and BRCA2...

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>

Adriana I. Apostol, Jacek Gronwald, Cezary Cybulski et al. Apr 01, 2026 pp. 883-892 10.1200/jco-25-01648

PURPOSE BRCA carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as...

Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging

Yunfeng Zhang, Xing Wang, Honglin Hu Apr 01, 2026 pp. 945-946 10.1200/jco-25-02107

Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus–Positive With Dual Stain and Human Papillomavirus Genotyping

Nicolas Wentzensen, Didem Egemen, Megan A. Clarke et al. Apr 01, 2026 pp. 840-848 10.1200/jco-25-00689

PURPOSE Primary human papillomavirus (HPV) testing has the best tradeoff of benefits and harms for cervical screening but requires triage to determine management among HPV positive...

Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis

Rahul Banerjee, Tracy King, Beth Faiman et al. Apr 01, 2026 pp. 903-913 10.1200/jco-25-01713

For over half a century, dexamethasone has been a backbone of treatment regimens for plasma cell disorders such as multiple myeloma (MM) and light-chain (AL) amyloidosis. Dexamethasone doses of approx...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page